No. Red Chip has distinguished itself as the only management company that provides all of the operational services that your Hemophilia Treatment Center will need to offer an exceptional 340B factor program to your patients with bleeding disorders.
Red Chip recently licensed an in-house pharmacy to enhance our service capabilities, but we’ll never compete with your HTC’s 340B factor program.
Red Chip is very familiar with billing various Medicaid programs across the United States. Each state decides how they will recognize 340B factor claims in their system, if at all.
Our billing experts closely adhere to the protocols of each Medicaid program that identifies and segregates 340B products within their reimbursement system, thus preventing duplicate discounting.
Red Chip maintains a list of clinicians at your HTC who are eligible to write prescriptions for your 340B program. We work closely with your HTC clinicians to ensure there is a current patient record.
Besides providing medications for a variety of hemostasis and thrombosis disorders, Red Chip also works with hematologists to provide medication for patients with Sickle Cell Disease.
Red Chip is working closely with pharmaceutical companies to support gene therapies and provide new medications for other rare, chronic diseases.